RTW Investments Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CG Oncology
CGON
|
+$282M |
| 2 |
Celcuity
CELC
|
+$271M |
| 3 |
Erasca
ERAS
|
+$189M |
| 4 |
Tango Therapeutics
TNGX
|
+$164M |
| 5 |
iRhythm Holdings
IRTC
|
+$70.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Penumbra
PEN
|
+$269M |
| 2 |
Axsome Therapeutics
AXSM
|
+$162M |
| 3 |
Insulet
PODD
|
+$92.3M |
| 4 |
MASI
Masimo
MASI
|
+$88.9M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$85.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.92% |
| 2 | Financials | 0.08% |
No holdings matched the selected filter criteria.
Similar funds
RTW Investments's Q1 2026 Portfolio in Review
As of Q1 2026, RTW Investments held 98 positions worth $10B, up 0.67% from $9.98B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
RTW Investments deployed $419M of net new capital in Q1 2026, opening 7 new positions and adding to 30 existing holdings. Its largest new stake was Waystar Holding Corp: 1,630,000 shares worth $39.3M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Apellis Pharmaceuticals, an estimated $85.8M trimmed.
- RTW Investments's largest Q1 2026 buy was Waystar Holding Corp: 1,630,000 shares worth $39.3M.
- RTW Investments added most to CG Oncology in Q1 2026, an estimated $282M increase.
- RTW Investments's biggest Q1 2026 reduction was Apellis Pharmaceuticals, cutting an estimated $85.8M.
- RTW Investments fully exited Penumbra in Q1 2026, selling an estimated $269M.
- RTW Investments's ten largest holdings make up 50% of its $10B portfolio in Q1 2026.
- RTW Investments opened 7 new positions and closed 10 in Q1 2026.
- RTW Investments's portfolio value rose 0.67% quarter-over-quarter to $10B.
Based on RTW Investments's 13F filing for Q1 2026, filed 15 May 2026.